A Phase 2 interventional study of vitamin D in Chronic Hepatitis C, sponsored by French National Agency for Research on AIDS and Viral Hepatitis. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by French National Agency for Research on AIDS and Viral Hepatitis · Phase 2, Interventional, and Treatment
Vitamin D deficiency is commonly found in patients with chronic hepatitis C. The investigators hypothesize that the correction of hypovitaminosis D before the initiation of anti-HCV combination therapy and the maintenance of an optimal vitamin D status during antiviral therapy could improve the antiviral efficacy
An open-label, prospective evaluation of the efficacy of vitamin D supplementation starting 1 month before and continuing for the duration of combination therapy with pegylated interferon alpha (2a or 2b) plus ribavirin in patients with chronic viral hepatitis C genotype 1 or 4, nonresponders to a first antiviral therapy.Vitamin D supplementation is started one month before antiviral therapy in order to introduce pegylated interferon plus ribavirin in patients with optimal vitamin D status
1,073 studies on the registry are indexed under Hepatitis C, Chronic; 9 are open to participants now.
This study's enrollment of 32 is below the median of 90 across 775 interventional studies indexed under Hepatitis C, Chronic.
Browse Hepatitis C, Chronic studies →French National Agency for Research on AIDS and Viral Hepatitis is the lead sponsor of 83 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: vitamin D
Vitamin D on top of the standard treatment
Negativity of HCV RNA below 12UI/mL after 12 weeks of antiviral combination therapy
Time frame: at week 12
Changes in HCV viral load after correction of vitamin D deficiency (delta log)
Time frame: at day 0
Changes in HCV viral load (delta log)
Time frame: at week 4
Changes in HCV viral load (delta log)
Time frame: at week 12
Negativity of HCV RNA below 12 UI/ml
Time frame: at week 24
Negativity of HCV RNA below 12 UI/ml
Time frame: at week 72
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
French National Agency for Research on AIDS and Viral Hepatitis